eosinophilic
AstraZeneca’s Fasenra Gains FDA Approval for Eosinophilic Granulomatosis with Polyangiitis, Expanding Treatment Options for Rare Autoimmune Disease
AstraZeneca, Fasenra, FDA approval, eosinophilic granulomatosis with polyangiitis (EGPA), rare autoimmune disease, biologic treatment, asthma medication, GSK’s Nucala
Docs Embrace Takeda’s Eohilia, Creating Competition for Sanofi, Regeneron’s Blockbuster Dupixent
Takeda, Eohilia, Dupixent, Sanofi, Regeneron, Chronic Inflammatory Disease, Eosinophilic Esophagitis